Affordable Access

deepdyve-link
Publisher Website

Diabetic retinopathy.

Authors
  • Cheung, Ning
  • Mitchell, Paul
  • Wong, Tien Yin
Type
Published Article
Journal
The Lancet
Publisher
Elsevier
Publication Date
Jul 10, 2010
Volume
376
Issue
9735
Pages
124–136
Identifiers
DOI: 10.1016/S0140-6736(09)62124-3
PMID: 20580421
Source
Medline
License
Unknown

Abstract

Diabetic retinopathy is a common and specific microvascular complication of diabetes, and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. Optimum control of blood glucose, blood pressure, and possibly blood lipids remains the foundation for reduction of risk of retinopathy development and progression. Timely laser therapy is effective for preservation of sight in proliferative retinopathy and macular oedema, but its ability to reverse visual loss is poor. Vitrectomy surgery might occasionally be needed for advanced retinopathy. New therapies, such as intraocular injection of steroids and antivascular endothelial growth-factor agents, are less destructive to the retina than are older therapies, and could be useful in patients who respond poorly to conventional therapy. The outlook for future treatment modalities, such as inhibition of other angiogenic factors, regenerative therapy, and topical therapy, is promising.

Report this publication

Statistics

Seen <100 times